Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma

Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma

Abstract Simultaneously targeting key pathogenic drivers and remodeling of the tumor microenvironment represents a critical therapeutic strategy for relapsed or refractory (r/r) multiple myeloma (MM) and lymphoma. Purinostat mesylate (PM), a highly selective HDAC I/II binhibitor, exhibits excellent...

Full description

Saved in:
Bibliographic Details
Main Authors: Linyu Yang, Qiang Qiu, Jie Wang, Yi Wen, He Li, Rui Liang, Yunyu Feng, Fang Wang, Xiaojing Lin, Minghai Tang, Jianhong Yang, Heying Pei, Peng Zhao, Jishi Wang, Jin Xiang, Jia Miao, Li Zheng, Ke Tan, Yongsheng Wang, Yiguo Hu, Lijuan Chen, Weili Zhao, Ting Niu
Format: Article
Language:English
Published: Nature Publishing Group 2025-06-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-025-02285-w
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://doi.org/10.1038/s41392-025-02285-w

Similar Items